![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/27/2905160/0/en/Allarity-Granted-Hearing-Before-Nasdaq-Panel-to-Present-Plan-of-Regaining-Compliance.html
https://www.globenewswire.com/news-release/2024/06/25/2903722/0/en/Allarity-Therapeutics-Dual-PARP-Tankyrase-Inhibitor-Stenoparib-Continues-to-Show-Extended-Clinical-Benefit-in-Advanced-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/05/20/2884790/0/en/Allarity-Therapeutics-Regains-Compliance-with-Nasdaq-s-Minimum-Stockholders-Equity-Requirement.html
https://www.globenewswire.com/news-release/2024/05/14/2881841/0/en/Allarity-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-including-Clear-Clinical-Benefits-from-Phase-2-Trial-NASDAQ-Compliance-and-Significant-Improvement-in-C.html
https://www.globenewswire.com/news-release/2024/05/07/2876853/0/en/Allarity-Therapeutics-Announces-that-All-Series-A-Preferred-and-All-Variable-Priced-Warrants-have-Converted-to-Common-Stock.html
https://www.globenewswire.com/news-release/2024/05/06/2875731/0/en/Allarity-Therapeutics-Exceeds-Nasdaq-s-Minimum-Equity-Requirement-Requests-Voluntarily-Withdrawal-of-Form-S-1.html
https://www.globenewswire.com/news-release/2024/05/02/2874113/0/en/Allarity-Therapeutics-Stenoparib-Shows-Clear-Clinical-Benefit-and-Achieves-Significant-Milestone-with-Early-Conclusion-of-Phase-2-Trial-in-Advanced-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/04/29/2871065/0/en/Allarity-Therapeutics-Regains-Compliance-with-NASDAQ-Minimum-Bid-Price-Requirement.html
https://www.globenewswire.com/news-release/2024/04/17/2864622/0/en/Allarity-Therapeutics-Receives-NASDAQ-Approved-Extension-to-Regain-Compliance-with-Nasdaq-Listing-Rule-5550-b-1.html
https://www.globenewswire.com/news-release/2024/04/04/2857867/0/en/Allarity-Therapeutics-Announces-1-for-20-Reverse-Stock-Split.html